[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |
Advanced search

EMEA (Europe, Middle East and Africa) Hospital-acquired Pneumonia (HAP) Drugs Market Report 2017

November 2017 | 114 pages | ID: E91AA346D5FEN
QYResearch

US$ 4,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
In this report, the EMEA Hospital-acquired Pneumonia (HAP) Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Hospital-acquired Pneumonia (HAP) Drugs for these regions, from 2012 to 2022 (forecast)
  • Europe: Germany, France, UK, Russia, Italy and Benelux;
  • Middle East: Saudi Arabia, Israel, UAE and Iran;
  • Africa: South Africa, Nigeria, Egypt and Algeria.
EMEA Hospital-acquired Pneumonia (HAP) Drugs market competition by top manufacturers/players, with Hospital-acquired Pneumonia (HAP) Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
  • Pfizer
  • GlaxoSmithKline
  • Merck
  • Mylan
  • Novartis
  • Teva Pharmaceutical Industries
  • AstraZeneca
  • Arsanis
  • Combioxin
  • Shinogi
  • Sun Pharmaceutical Industries
  • The Medicines Company
  • Theravance Biopharma
On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
  • Antibacterial
  • Antiviral
  • Antifungal
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
  • Hospitals
  • Clinics
  • Other
If you have any special requirements, please let us know and we will offer you the report as you want.
EMEA (Europe, Middle East and Africa) Hospital-acquired Pneumonia (HAP) Drugs Market Report 2017

1 HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS OVERVIEW

1.1 Product Overview and Scope of Hospital-acquired Pneumonia (HAP) Drugs
1.2 Classification of Hospital-acquired Pneumonia (HAP) Drugs
  1.2.1 EMEA Hospital-acquired Pneumonia (HAP) Drugs Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Hospital-acquired Pneumonia (HAP) Drugs Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Antibacterial
  1.2.4 Antiviral
  1.2.5 Antifungal
1.3 EMEA Hospital-acquired Pneumonia (HAP) Drugs Market by Application/End Users
  1.3.1 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Hospitals
  1.3.3 Clinics
  1.3.4 Other
1.4 EMEA Hospital-acquired Pneumonia (HAP) Drugs Market by Region
  1.4.1 EMEA Hospital-acquired Pneumonia (HAP) Drugs Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Hospital-acquired Pneumonia (HAP) Drugs (2012-2022)
  1.5.1 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2022)

2 EMEA HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Hospital-acquired Pneumonia (HAP) Drugs Market Competition by Players/Manufacturers
  2.1.1 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sale Price by Players (2012-2017)
2.2 EMEA Hospital-acquired Pneumonia (HAP) Drugs (Volume and Value) by Type/Product Category
  2.2.1 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sale Price by Type (2012-2017)
2.3 EMEA Hospital-acquired Pneumonia (HAP) Drugs (Volume) by Application
2.4 EMEA Hospital-acquired Pneumonia (HAP) Drugs (Volume and Value) by Region
  2.4.1 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Price by Region (2012-2017)

3 EUROPE HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales and Value (2012-2017)
  3.1.1 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2017)
3.2 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Type
3.3 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Application
3.4 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Volume by Countries (2012-2017)
  3.4.2 Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue by Countries (2012-2017)
  3.4.3 Germany Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
  3.4.4 France Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
  3.4.5 UK Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
  3.4.6 Russia Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
  3.4.7 Italy Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)

4 MIDDLE EAST HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales and Value (2012-2017)
  4.1.1 Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2017)
4.2 Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Type
4.3 Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Application
4.4 Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Hospital-acquired Pneumonia (HAP) Drugs Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
  4.4.4 Israel Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
  4.4.5 UAE Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
  4.4.6 Iran Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)

5 AFRICA HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Hospital-acquired Pneumonia (HAP) Drugs Sales and Value (2012-2017)
  5.1.1 Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2017)
5.2 Africa Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Type
5.3 Africa Hospital-acquired Pneumonia (HAP) Drugs Sales and Market Share by Application
5.4 Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Volume by Countries (2012-2017)
  5.4.2 Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue by Countries (2012-2017)
  5.4.3 South Africa Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate (2012-2017)

6 EMEA HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Pfizer
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Hospital-acquired Pneumonia (HAP) Drugs Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 GlaxoSmithKline
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Hospital-acquired Pneumonia (HAP) Drugs Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Merck
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Hospital-acquired Pneumonia (HAP) Drugs Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Merck Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Mylan
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Hospital-acquired Pneumonia (HAP) Drugs Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 Novartis
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Hospital-acquired Pneumonia (HAP) Drugs Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Teva Pharmaceutical Industries
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Hospital-acquired Pneumonia (HAP) Drugs Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 AstraZeneca
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Hospital-acquired Pneumonia (HAP) Drugs Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Arsanis
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Hospital-acquired Pneumonia (HAP) Drugs Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Combioxin
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Hospital-acquired Pneumonia (HAP) Drugs Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Shinogi
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Hospital-acquired Pneumonia (HAP) Drugs Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Sun Pharmaceutical Industries
6.12 The Medicines Company
6.13 Theravance Biopharma

7 HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS MANUFACTURING COST ANALYSIS

7.1 Hospital-acquired Pneumonia (HAP) Drugs Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Hospital-acquired Pneumonia (HAP) Drugs

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Hospital-acquired Pneumonia (HAP) Drugs Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Hospital-acquired Pneumonia (HAP) Drugs Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA HOSPITAL-ACQUIRED PNEUMONIA (HAP) DRUGS MARKET FORECAST (2017-2022)

11.1 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Hospital-acquired Pneumonia (HAP) Drugs Price and Trend Forecast (2017-2022)
11.2 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Hospital-acquired Pneumonia (HAP) Drugs Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Forecast by Type (2017-2022)
11.7 EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.


LIST OF TABLES AND FIGURES

Figure Product Picture of Hospital-acquired Pneumonia (HAP) Drugs
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs) by Type (2012-2022)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Volume Market Share by Type (Product Category) in 2016
Figure Antibacterial Product Picture
Figure Antiviral Product Picture
Figure Antifungal Product Picture
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs) by Application (2012-2022)
Figure EMEA Sales Market Share of Hospital-acquired Pneumonia (HAP) Drugs by Application in 2016
Figure Hospitals Examples
Table Key Downstream Customer in Hospitals
Figure Clinics Examples
Table Key Downstream Customer in Clinics
Figure Other Examples
Table Key Downstream Customer in Other
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Market Size (Million USD) by Region (2012-2022)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Volume and Growth Rate (2012-2022)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Market Major Players Product Sales Volume (K Pcs) (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs) of Major Players (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Players (2012-2017)
Figure 2016 Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Players
Figure 2017 Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Players
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) by Players (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Players (2012-2017)
Table 2016 EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Players
Table 2017 EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Players
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sale Price (USD/Pcs) by Players (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Market Share by Type (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Type (2012-2017)
Figure Sales Market Share of Hospital-acquired Pneumonia (HAP) Drugs by Type (2012-2017)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Hospital-acquired Pneumonia (HAP) Drugs by Type in 2016
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sale Price (USD/Pcs) by Type (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Market Share by Application (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Application (2012-2017)
Figure Sales Market Share of Hospital-acquired Pneumonia (HAP) Drugs by Application (2012-2017)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Application in 2016
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Market Share by Region (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Share by Region (2012-2017)
Figure Sales Market Share of Hospital-acquired Pneumonia (HAP) Drugs by Region (2012-2017)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in 2016
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Hospital-acquired Pneumonia (HAP) Drugs by Region (2012-2017)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share Regions in 2016
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Price (USD/Pcs) by Region (2012-2017)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate (2012-2017)
Table Europe Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) by Type (2012-2017)
Table Europe Hospital-acquired Pneumonia (HAP) Drugs Market Share by Type (2012-2017)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Market Share by Type in 2016
Table Europe Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) by Application (2012-2017)
Table Europe Hospital-acquired Pneumonia (HAP) Drugs Market Share by Application (2012-2017)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Market Share by Application in 2016
Table Europe Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) by Countries (2012-2017)
Table Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries (2012-2017)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries in 2016
Table Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2012-2017)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries in 2016
Figure Germany Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure France Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure UK Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Russia Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Italy Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Benelux Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Middle East Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) by Type (2012-2017)
Table Middle East Hospital-acquired Pneumonia (HAP) Drugs Market Share by Type (2012-2017)
Figure Middle East Hospital-acquired Pneumonia (HAP) Drugs Market Share by Type (2012-2017)
Table Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) by Applications (2012-2017)
Table Middle East Hospital-acquired Pneumonia (HAP) Drugs Market Share by Applications (2012-2017)
Figure Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Application in 2016
Table Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs) by Countries (2012-2017)
Table Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales Volume Market Share by Countries in 2016
Table Middle East Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Middle East Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2012-2017)
Figure Middle East Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries in 2016
Figure Saudi Arabia Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Israel Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure UAE Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Iran Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) by Type (2012-2017)
Table Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2012-2017)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Type (2012-2017)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Type in 2016
Table Africa Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) by Application (2012-2017)
Table Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2012-2017)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Application (2012-2017)
Table Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Volume (K Pcs) by Countries (2012-2017)
Table Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries (2012-2017)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share by Countries in 2016
Table Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) by Countries (2012-2017)
Table Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries (2012-2017)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share by Countries in 2016
Figure South Africa Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Nigeria Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Egypt Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Algeria Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Table Pfizer Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Pfizer Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in EMEA (2012-2017)
Figure Pfizer Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in EMEA (2012-2017)
Table GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in EMEA (2012-2017)
Figure GlaxoSmithKline Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in EMEA (2012-2017)
Table Merck Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table Merck Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Merck Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Merck Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in EMEA (2012-2017)
Figure Merck Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in EMEA (2012-2017)
Table Mylan Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Mylan Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in EMEA (2012-2017)
Figure Mylan Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in EMEA (2012-2017)
Table Novartis Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Novartis Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in EMEA (2012-2017)
Figure Novartis Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in EMEA (2012-2017)
Table Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in EMEA (2012-2017)
Figure Teva Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in EMEA (2012-2017)
Table AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in EMEA (2012-2017)
Figure AstraZeneca Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in EMEA (2012-2017)
Table Arsanis Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Arsanis Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in EMEA (2012-2017)
Figure Arsanis Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in EMEA (2012-2017)
Table Combioxin Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Combioxin Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in EMEA (2012-2017)
Figure Combioxin Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in EMEA (2012-2017)
Table Shinogi Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (2012-2017)
Figure Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate (2012-2017)
Figure Shinogi Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share in EMEA (2012-2017)
Figure Shinogi Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share in EMEA (2012-2017)
Table Sun Pharmaceutical Industries Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table The Medicines Company Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table Theravance Biopharma Hospital-acquired Pneumonia (HAP) Drugs Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Hospital-acquired Pneumonia (HAP) Drugs
Figure Manufacturing Process Analysis of Hospital-acquired Pneumonia (HAP) Drugs
Figure Hospital-acquired Pneumonia (HAP) Drugs Industrial Chain Analysis
Table Raw Materials Sources of Hospital-acquired Pneumonia (HAP) Drugs Major Manufacturers in 2016
Table Major Buyers of Hospital-acquired Pneumonia (HAP) Drugs
Table Distributors/Traders List
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) and Growth Rate Forecast (2017-2022)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Price (USD/Pcs) and Trend Forecast (2017-2022)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) Forecast by Region (2017-2022)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Region (2017-2022)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share Forecast by Region (2017-2022)
Table Europe Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Middle East Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) Forecast by Countries (2017-2022)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Countries (2017-2022)
Table Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Hospital-acquired Pneumonia (HAP) Drugs Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) Forecast by Type (2017-2022)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Type (2017-2022)
Table EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales (K Pcs) Forecast by Application (2017-2022)
Figure EMEA Hospital-acquired Pneumonia (HAP) Drugs Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

More Publications

Need Help?

Ask a Question

Market Reports

All Categories